Rising Geriatric Population Base All Around the Globe is a Major Factor Fostering the Growth of the Primary Angle-Closure Glaucoma Market

Glaucoma is more common in people over 60, family members of those already diagnosed with the disease, steroid users, diabetics, and those with high myopia, hypertension, a central cornea thickness of less than 5 mm, and eye injury. Glaucoma is anticipated to affect around 85 million individuals by 2022, with that figure expected to rise to 111.8 million by 2040.

Access Full Report @ https://www.databridgemarketresearch.com/ar/reports/global-primary-angle-closure-glaucoma-market

Global primary angle-closure glaucoma market is expected to reach USD 340.82 million by 2028 from USD 217.01 million in 2020, growing with a CAGR of 6.1% in the forecast period of 2021 to 2028. Increasing demand for advanced medical technologies for diagnostic and treatment purposes and the increasing population of women and greater female to male ratio in angle closure glaucoma due to various anatomical and hormonal factors are some of the drivers boosting the market's growth. Rising geriatric population base, increasing awareness about the availability of treatment options in the developing economies and increasing personal disposable income are some other important market growth determinants.

Rise in the geriatric population base globally is expected to drive the market's growth rate

Geriatric population is the most susceptible to developing chronic diseases and disorders. Therefore, rising geriatric populace all around the world is extremely vulnerable to developing eye related diseases and disorders and other chronic diseases. This in turn will act as an important market growth determinant. Increased expenditure by public and private players on the development of healthcare infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced healthcare technologies will yet again widen the scope of growth.  

Report Scope and Market Segmentation

Segment Analysis:

Global primary angle-closure glaucoma market is categorized into four notable segments which are based on disease type, type, end user and distribution channel.

• On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, the acute angle-closure glaucoma segment is expected to dominate the market with 71.6% market share due to the high incidence cases for acute cases. Acute attack of angle closure glaucoma is at high risk and the maximum number of cases which ophthalmologist diagnose are of acute angle closure glaucoma.
• On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market with 72.31% market share due to the primary test and secondary testing options available for the diagnosis and physicians only prefer the medical procedure after a proper diagnosis. Treatment segment in this market is totally based on surgical intervention due to which the market share for treatment is less than diagnosis.
• On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers, others. In 2021, the hospitals segment is expected to dominate the market with 46.40% market share. This segment specializes in conducting various surgical intervention and has a large professional's portfolio available for proper treatment. Moreover, cost-effective and high quality diagnostic care and services in safe healthcare environment and are convenient for consulting physician/healthcare institution to outsource bulk diagnostics tests to independent diagnostic laboratories for better customer services.

Hospital dominates the end user segment of the primary angle-closure glaucoma market

Rising number of hospitals and clinics especially in the developing economies is fostering the growth of this segment. Moreover, this segment is specialized in conducting various surgical intervention and have a large professional's portfolio available for giving the proper treatment. This will yet again bolster the growth and dominance of this segment.

• On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, the direct tender segment is expected to dominate the market with 66.79% market share. They are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics. With the increasing cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers.

Direct tender dominates the distribution channel segment of the primary angle-closure glaucoma market

In 2021, direct tender segment will emerge as the dominating segment with 66.79% market share. This is because of the cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. Also, growth and expansion of the direct tender distribution channel will yet again bolster the growth and dominance of this segment.

Major Players

Data Bridge Market Research recognizes the following companies as the major Down syndrome market players in advanced wound care market are Allergan (Ireland), Bausch & Lomb Incorporated (Canada), NOVAEYE MEDICAL (Australia), ZEISS International (Germany), Alcon Inc. (Switzerland), LIGHTMED (U.S.), Luneau Technology USA (U.S.), Reichert, Inc. (U.S.) and NEW VISION (Uganda).

Market Development – 

• In October 2019, MicroSurgical Technology announced that they have acquired the Trabectome and Goniotome surgical system from Neomedix Corporation. Trabectome is used in major surgical technology for glaucoma. This acquisition increased the company's product portfolio and enhanced the profit for the company. Trabectome achieves long-term IOP reduction by removing the trabecular meshwork via electrosurgical ablation. Goniotome I/A helps maintain a stable, clean anterior chamber while enhancing angle visibility, while Goniotome excises the trabecular meshwork with serrated blades.
• Johnson & Johnson Vision Care, Inc. announced in June 2020 that it will donate to Optometry Cares - The American Optometric Association Foundation (AOA) Foundation and the American Academy of Optometry Foundation. As an AOA Recovery Partner, Johnson & Johnson Vision will make a donation to Optometry Cares, the charitable Foundation of the AOA, optometry's premier philanthropic and charitable organisation dedicated to expanding eye health and vision care access to everyone in the United States in order to enhance human performance a total of USD 0.30 million was donated by the company for the practitioner in their support to provide eye care to the community affected by COVID-19. The money will go to practitioners who have been uniquely affected by COVID-19.
• Aerie Pharmaceuticals and Santen Pharmaceuticals partnered in December 2021 to develop and market Rhopressa/Rhokiinsa and Rocklatan/Roclanda for glaucoma therapy in Europe, India, China, Oceania, and parts of Latin America. Both companies' market positions in these regions will be strengthened as a result of this. Aerie will get a $50 million upfront payment as well as up to $99 million in development and sales milestones under the terms of the agreement. Aerie is also eligible for additional compensation in excess of 25% of the items' net sales, which includes the cost of supplies supplied by Aerie to Santen as well as a royalty for Aerie's intellectual property. Santen will be in charge of the products' sales, marketing, and pricing decisions.

Regional Analysis

Geographically, the countries covered in the primary angle-closure glaucoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in primary angle-closure glaucoma market during the forecast period 2021 - 2028

North America is dominating the global primary angle-closure glaucoma market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. The U.S. is dominating due to the presence of major market players which provide the wide drug portfolio and well-developed healthcare infrastructure in this region. The U.S. has the highest household spending in the world and higher diagnosis segment as well as treatment rate making it the largest market for primary angle-closure glaucoma products. Also, existence of advanced healthcare technologies in this region is another reason for this region's dominance in the global market.   

Asia-Pacific is estimated to be the fastest growing region in primary angle-closure glaucoma market the forecast period 2021 - 2028

Asia-Pacific is expected to grow during the forecast period due to the increasing patient population and rapid development of infrastructural facilities in emerging economies in this region. In addition to this, rising level of private and public expenditure on the development of healthcare industry infrastructure in the developing and backward economies and increasing per-capita income are expected propel the market's growth rate in this region. Japan is expected to dominate in the market in the Asia-Pacific as Japan is one of the leading countries in the world with rapidly increasing product usage and diagnosis segment rate with rising awareness regarding primary angle-closure glaucoma. Also, increasing geriatric population base, surging incidence rate of chronic and acute disorders and diseases and rising medical tourism are some other important market growth determinants.

COVID-19 Impact Analysis

Due to the adoption of preventive lockdown in various economies, the COVID-19 pandemic had a modest negative influence on glaucoma treatment market sales. Due to a lack of healthcare infrastructure, COVID 19 patients were given priority and all resources were mobilised. In addition, several ophthalmology departments were transformed into COVID-19 wards, limiting glaucoma patient follow-up. Furthermore, lower demand for market has occurred from less patient visits to clinical settings due to concern of infection among elderly persons. During the pandemic, however, the use of telemedicine platforms aided patients in receiving treatment on time, propelling the broader business forward.

For more detailed information about the primary angle-closure glaucoma market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-down-syndrome-market